Study of Sildenafil Citrate During and After Radiotherapy/Hormone Therapy for Erectile Function Versus Radiotherapy/Hormone Therapy for Prostate Cancer

• ClinicalTrials.gov Identifier: NCT00142506
• Recruitment Status: Completed
• First Posted: September 2, 2005
• Results First Posted: October 20, 2017
• Last Update Posted: October 20, 2017
• Sponsor: Memorial Sloan Kettering Cancer Center
• Collaborators: Icahn School of Medicine at Mount Sinai; Beth Israel Medical Center; St. Luke's-Roosevelt Hospital Center
• Information provided by (Responsible Party): Memorial Sloan Kettering Cancer Center

Study Description

Brief Summary:

Radiation sometimes affects the ability for a person to have a normal erection. Complete loss of erections after radiation treatment can happen in 40-50% of treated patients. There are medications, like sildenafil (also known as Viagra), that can help the ability to get back erections in almost 70% of such patients.

The purpose of this study is to see if taking Viagra every day starting right before, during and for about 6 months after treatment, could reduce the risk of long-term erectile dysfunction.

Condition or disease	Intervention/treatment	Phase
Prostate Cancer; Erectile Dysfunction	Drug: sildenafil citrate and questionaires; Drug: placebo tablets and questionaires	Phase 3

Detailed Description:

This protocol is a randomized prospective study comparing prophylactic and on demand Sildenafil Citrate usage administered during and after radiotherapy in combination with or without hormone therapy versus radiotherapy alone for the preservation of erectile function in potent patients with clinically localized prostate cancer. The primary objectives of this protocol are to determine if prophylactic and on demand usage of Sildenafil Citrate can preserve spontaneous erectile function as well as diminish the time to restoration of erectile function in potent men receiving radiotherapy with or without hormone therapy for localized prostate cancer. Secondary objectives of this study are: to determine whether prophylactic and on demand use of Sildenafil Citrate during therapy may improve the long-term response to the drug following treatment; to determine whether prophylactic and on demand use of Sildenafil Citrate during therapy will reduce acute and late urinary effects of radiotherapy; to determine the impact of dosimetry and radiation exposure to both the neurovascular bundle and bulb of the penis on erectile function preservation in the study population undergoing brachytherapy and hormone therapy; to asses the impact on quality of life following prophylactic and on demand Sildenafil Citrate usage in the study population; to determine the relationship between testosterone levels, erectile function and efficacy of prophylactic and on demand Sildenafil Citrate usage in the study population.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 290 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Prevention
• Official Title: This Protocol is a Randomized Prospective Study Comparing Prophylactic and on Demand Sildenafil Citrate Usage Administered During and After Radiotherapy With or Without Hormone Therapy Versus Radiotherapy With or Without Hormone Therapy Alone for the Preservation of Erectile Function After Therapy for Potent Patients With Clinically Localized Prostate Cancer
• Study Start Date: February 2005
• Actual Primary Completion Date: April 2014
• Actual Study Completion Date: April 2014

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: 1; radiotherapy with hormones, questionaire assessments	Drug: sildenafil citrate and questionaires; Hormone therapy patients will be instructed to begin the study drug simultaneously or within 1 month of start of hormone therapy. These patients will then continue to take the study drug for approximately 6 months following start of radiotherapy.In addition, during prophylactic phase (drug and placebo prophylactic arms) patients will have the opportunity to utilize oral 50 mg. tablets of Sildenafil Citrate in an on demand open label, flexible dose fashion. Hormone patients will be offered on demand Sildenafil for approximately 15-21 months. Hormone therapy patients will complete assessments at baseline (within 4 weeks of start of study treatment) each month (only IIEF and QOL) before start of radiotherapy, at start of radiotherapy and at months 3, 6, 9, 12 18 and 24 from start of radiotherapy. Testosterone assessments will take place at baseline, and months 12 and 24.
Placebo Comparator: 2; radiotherapy without hormones, questionaire assessments	Drug: placebo tablets and questionaires; Non-hormone therapy patients will be instructed to begin the study drug 3 days prior to start of radiotherapy. Patients beginning study drug anytime between 3 days before start of radiotherapy and 2 weeks after the first day of radiotherapy will also be acceptable. These patients will then continue to take the study drug for approximately 6 months following start of radiotherapy. In addition, during prophylactic phase (drug and placebo prophylactic arms) patients will have the opportunity to utilize oral 50 mg. tablets of Sildenafil Citrate in an on demand, open label, flexible dose fashion. Non-hormone patients will be offered on demand Sildenafil for approximately 12 months. Assessments (IIEF, IPSS, QOL) will be completed by non-hormone therapy patients at baseline (within 4 weeks of start of study treatment) and at approximately months 3, 6, 9, 12, 18 and 24 from start of radiotherapy. Testosterone assessments will take place at baseline, and months 12 and 24.

Outcome Measures

Primary Outcome Measures :

1. Assessment of Erectile Dysfunction [ Time Frame: Baseline, 6 months, 12 months, 24 months ]
   The International Index of Erectile Function (IIEF) is used for the evaluation of male sexual function and diagnostic evaluation of Erectile Dysfunction (ED) severity. There are 5 domains of the IIEF: erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction. A score of 0-5 is awarded to each question of the IIEF. Total IIEF scores range from 0-75. Lower scores indicate severe erectile dysfunction (0=severe erectile dysfunction), while higher scores indicate less erectile dysfunction (75=no erectile dysfunction).

Eligibility Criteria

• Ages Eligible for Study: Child, Adult, Older Adult
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• To receive external beam radiation therapy and/or brachytherapy for biopsy-proven prostate cancer.
• Baseline International Index of Erectile Function (IIEF) erectile function domain score >= 17.
• Patients receiving radiotherapy with hormone therapy undergoing a maximum of 9 months of hormone therapy will be acceptable.

Exclusion Criteria:

• Baseline IIEF-EF (1-30) domain score of <17 pre-therapy
• Current routine use of erectogenic agents (use of agents > 4 times per month would constitute "routine use")
• Neoadjuvant androgen deprivation therapy started more than 1 month prior to entry into study (intake of Bicalutamide alone does not constitute exclusion from study entry)
• Have a clinically significant penile deformity in the opinion of the investigator (ie: Peyronie's Disease)
• Non-organ confined disease
• Prior prostate surgery or cryotherapy
• Prior prostate radiotherapy started more than 2 weeks prior to entry into study
• Currently taking 0.8mg Flomax daily
• Penile implant history
• Present at baseline with chronic angina requiring nitrates, angina occurring during sexual intercourse or unstable angina within the last 6 months.
• History of myocardial infarction, coronary artery bypass graft surgery or percutaneous coronary intervention within 90 days of baseline visit.
• History of significant cardiac conduction defect within 90 days of baseline visit.
• Exhibit systolic blood pressure > 170 or < 90 mm Hg or diastolic blood pressure > 100 or < 50 mm Hg at baseline visit or have a history of malignant hypertension
• Have any condition that would interfere with the subject's ability to provide informed consent or comply with study instructions, would place subject at increased risk, or might confound the interpretation of the study results
• Currently receive treatment with nitrates, cancer chemotherapy, or antiandrogens (except finasteride taken as Propecia or Proscar)
• Have a history of drug, alcohol, or substance abuse within the past 6 months, as assessed by the investigator.

Contacts and Locations

Locations

United States, New Jersey

Memorial Sloan-Kettering Cancer Center at Basking Ridge

Basking Ridge, New Jersey, United States, 07920

United States, New York

Memorial Sloan-Kettering Cancer Center at Commack

Commack, New York, United States, 11725

Memorial Sloan-Kettering Cancer Center

New York, New York, United States, 10021

Memorial Sloan-Kettering Cancer Center at Mercy Medical Center

Rockville Centre, New York, United States, 11570

Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center

Sleepy Hollow, New York, United States, 10591

Sponsors and Collaborators

Memorial Sloan Kettering Cancer Center

Icahn School of Medicine at Mount Sinai

Beth Israel Medical Center

St. Luke's-Roosevelt Hospital Center

Investigators

• Principal Investigator: Michael J Zelefsky, M.D.; Memorial Sloan Kettering Cancer Center

More Information

Additional Information:

Memorial Sloan-Kettering Cancer Center 

• Responsible Party: Memorial Sloan Kettering Cancer Center
• ClinicalTrials.gov Identifier: NCT00142506
• Other Study ID Numbers: 05-007
• First Posted: September 2, 2005
• Results First Posted: October 20, 2017
• Last Update Posted: October 20, 2017
• Last Verified: September 2017

Keywords provided by Memorial Sloan Kettering Cancer Center:

Prostate Cancer; Cancer of the Prostate; Prostate Neoplasms; Prostatic Cancer; Viagra; 05-007

Additional relevant MeSH terms:

Prostatic Neoplasms; Erectile Dysfunction; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Prostatic Diseases; Sexual Dysfunction, Physiological; Sexual Dysfunctions, Psychological; Mental Disorders; Sildenafil Citrate; Molecular Mechanisms of Pharmacological Action; Vasodilator Agents; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Enzyme Inhibitors; Urological Agents